Objective To explore short-term clinical efficacy and safety of recombinant human endostatin and bozhi glycopeptide combined with chemotherapy scheme in the treatment of advanced non-small cell lung cancer. Methods From January 2012 to April 2014,102 patients admitted into our hospital and confirmed as advanced non-small cell lung cancer by pathological diagnosis were divided into two groups.The control group (48 patients) was given chemotherapy scheme of oxaliplatin (L-OHP)+pemetrexed (PEM).The experiment group (54 patients) were given recom-binant human endostatin and bozhi glycopeptide on the basis of control group.Then the clinical effect,KPS score of life quality,the incidence rate of drug toxicity reaction and the change of immune function of peripheral blood between two groups was compared respectively. Results After treatment,short-term clinical effect and KPS score of life quality of the experiment group was better than that of control group respectively (P<0.05).CD4+,CD8+after treatment in patients of two groups was decreased respectively compared with before treatment,and control group was more obvious,and there was a statistical difference of CD4+,CD8+after treatment between two groups (P<0.05). Conclusion Recombinant human endostatin combined with bozhi glycopeptide has a better short-term effect in the treatment of advanced non-small cell lung cancer and can enhance patients’life quality in the process of chemical therapy and improve the immune function of patients.%目的：探讨重组人血管内皮抑素与薄芝糖肽联合化疗治疗晚期非小细胞肺癌的近期临床效果和安全性。方法选取2012年1月~2014年4月来本院就诊的102例经病理证实的晚期非小细胞肺癌患者，根据治疗方法，将患者分为两组。对照组48例单纯给予奥沙利铂(L-OHP)+培美曲塞(PEM)化疗方案；实验组54例在对照组基础上给予重组人血管内皮抑素和薄芝糖肽治疗。比较两组患者的临床疗效、生活质量KPS评分、药物毒性反应发生率以及外周血免疫功能变化情况。结果治疗后，实验组患者的近期临床疗效、生活质量KPS评分优于对照组(P<0.05)。两组患者治疗后的CD4+、CD8+均较治疗前降低，对照组降低更明显，两组治疗后的CD4+、CD8+差异有统计学意义(P<0.05)。结论重组人血管内皮抑素与薄芝糖肽联合化疗治疗晚期非小细胞肺癌具有较好的近期效果，能提高患者在化疗过程中的生活质量，改善其免疫功能。
展开▼
